Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome

Boehringer Ingelheim

Status: Completed

Conditions: Arthritis, Rheumatoid

Treatments: Drug: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac; Drug: Meloxicam

Study type: Observational

Funder types: Industry

Identifiers

NCT02180516

107.246

Details and patient eligibility

About

Study to assess the safety profile of meloxicam by comparing incidence of gastrointestinal adverse events of meloxicam with that of NSAID in the routine daily therapeutic situation.

Enrollment: 9,984 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Indications according to the package insert of the prescribed NSAID

Exclusion criteria

• There is no exclusion criterion, because this Post Marketing Study is an observational study

Trial design

9,984 participants in 2 patient groups

Meloxicam

Treatment:

Drug: Meloxicam

Other NSAIDs

Treatment:

Drug: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac